Related Experiment Videos
DRD3 and DAT1 genes in schizophrenia: an association study
R Joober1, A Toulouse, C Benkelfat
1Douglas Hospital Research Centre, 6875 Boulevard LaSalle, H4H 1R3, Verdun, Canada. rjoobe@po-box.mcgill.ca
Journal of Psychiatric Research
|December 6, 2000
Summary
This study found no significant association between dopamine receptor 3 (DRD3) and dopamine transporter 1 (DAT1) gene variants and schizophrenia susceptibility or phenotype in the studied population.
Area of Science:
- Neurogenetics
- Psychiatric Genetics
Background:
- Schizophrenia is a complex psychiatric disorder with a significant genetic component.
- Dopamine pathways, involving dopamine receptor 3 (DRD3) and dopamine transporter 1 (DAT1) genes, are implicated in schizophrenia pathophysiology.
Purpose of the Study:
- To investigate the potential role of DRD3 and DAT1 gene polymorphisms in schizophrenia susceptibility.
- To examine if these gene variants influence schizophrenia phenotype, including neuroleptic response and clinical characteristics.
Main Methods:
- Genotyping of DRD3 (Ser9Gly) and DAT1 (VNTR) polymorphisms in schizophrenic patients (responders and non-responders) and healthy controls.
- Comparison of allelic distributions and analysis of clinical parameters (age at onset, attention, family history) across different genotypes.
Main Results:
- No significant differences in DRD3 or DAT1 allelic frequencies were found between patients and controls.
- A non-significant trend suggested an excess of DRD3 Gly/Gly genotype in neuroleptic non-responders.
- No genotype-phenotype correlations were observed for age at onset, attention, or family loading.
Conclusions:
- The studied DRD3 and DAT1 polymorphisms do not appear to confer susceptibility to schizophrenia in this population.
- These genes do not significantly modulate the phenotype of schizophrenia, including neuroleptic response or clinical features.